• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4602291)   Today's Articles (5045)   Subscriber (49367)
For: Iacovelli R, Verri E, Cossu Rocca M, Aurilio G, Cullurà D, Santoni M, de Cobelli O, Nolé F. Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. Crit Rev Oncol Hematol 2016;99:324-31. [DOI: 10.1016/j.critrevonc.2016.01.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2015] [Revised: 11/30/2015] [Accepted: 01/14/2016] [Indexed: 01/08/2023]  Open
Number Cited by Other Article(s)
1
Jordan AR, Wang J, Yates TJ, Hasanali SL, Lokeshwar SD, Morera DS, Shamaladevi N, Li CS, Klaassen Z, Terris MK, Thangaraju M, Singh AB, Soloway MS, Lokeshwar VB. Molecular targeting of renal cell carcinoma by an oral combination. Oncogenesis 2020;9:52. [PMID: 32427869 PMCID: PMC7237463 DOI: 10.1038/s41389-020-0233-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Revised: 04/17/2020] [Accepted: 04/23/2020] [Indexed: 02/06/2023]  Open
2
Liu XL, Xue HY, Chu Q, Liu JY, Li J. Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e19570. [PMID: 32221075 PMCID: PMC7220148 DOI: 10.1097/md.0000000000019570] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]  Open
3
Procopio G, Apollonio G, Cognetti F, Miceli R, Milella M, Mosca A, Chiuri VE, Bearz A, Morelli F, Ortega C, Atzori F, Donini M, Ratta R, Raimondi A, Claps M, Martinetti A, Capitanio U, de Braud FG, Cappelletti V, Verzoni E. Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. Eur Urol Oncol 2019;2:699-707. [PMID: 31542243 DOI: 10.1016/j.euo.2019.08.011] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2019] [Revised: 08/21/2019] [Accepted: 08/30/2019] [Indexed: 01/15/2023]
4
Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol Res 2019;144:19-50. [DOI: 10.1016/j.phrs.2019.03.006] [Citation(s) in RCA: 290] [Impact Index Per Article: 58.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/06/2019] [Accepted: 03/07/2019] [Indexed: 12/14/2022]
5
Wang HT, Xia M. A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma. Medicine (Baltimore) 2019;98:e13779. [PMID: 30608388 PMCID: PMC6344165 DOI: 10.1097/md.0000000000013779] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]  Open
6
Huang HF, Fan XR, Ji ZG. The Effectiveness of Sorafenib over Other Targeted Agents in the Second-Line Treatment of Metastatic Renal Cell Carcinoma: a Meta-Analysis. Pathol Oncol Res 2018;25:1497-1503. [PMID: 30421088 DOI: 10.1007/s12253-018-0516-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2017] [Accepted: 10/21/2018] [Indexed: 12/23/2022]
7
Pauty J, Usuba R, Cheng IG, Hespel L, Takahashi H, Kato K, Kobayashi M, Nakajima H, Lee E, Yger F, Soncin F, Matsunaga YT. A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs. EBioMedicine 2018;27:225-236. [PMID: 29289530 PMCID: PMC5828365 DOI: 10.1016/j.ebiom.2017.12.014] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2017] [Revised: 12/06/2017] [Accepted: 12/14/2017] [Indexed: 10/26/2022]  Open
8
Randrup Hansen C, Grimm D, Bauer J, Wehland M, Magnusson NE. Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma. Int J Mol Sci 2017;18:ijms18020461. [PMID: 28230776 PMCID: PMC5343994 DOI: 10.3390/ijms18020461] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2017] [Revised: 02/13/2017] [Accepted: 02/17/2017] [Indexed: 02/07/2023]  Open
9
Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study. BIOMED RESEARCH INTERNATIONAL 2017;2017:9215930. [PMID: 28271073 PMCID: PMC5320076 DOI: 10.1155/2017/9215930] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Revised: 09/20/2016] [Accepted: 10/10/2016] [Indexed: 12/16/2022]
10
Zaffuto E, Karakiewicz PI, Capitanio U. Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next? ANNALS OF TRANSLATIONAL MEDICINE 2016;4:291. [PMID: 27568482 DOI: 10.21037/atm.2016.06.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA